| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/21/2001 | CA2207348C Benzimidazole derivatives |
| 08/21/2001 | CA2196845C Hydroxamic acid compounds |
| 08/21/2001 | CA2093793C Alkylidene analogs of 1'-aminospiro¬isoquinoline-4(1h),-3'-pyrrolidine|1,2',3,5'(2h)-tetrones useful as aldose reductase inhibitors |
| 08/21/2001 | CA2060652C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 08/18/2001 | CA2337786A1 New derivatives of phosphonic 6-sulfamoyl-3-quinolyl acids, the process for the preparation thereof and the pharmaceutical compounds containing them |
| 08/18/2001 | CA2337785A1 New derivatives of phosphonic 6-amino or 6-hydrazinosulfonyl-3-quinolinyl acids, the process for the preparation thereof and the pharmaceutical compounds containing them |
| 08/18/2001 | CA2337301A1 New quinolinyl phosphonic aryl or heteroaryl acid derivatives, their preparation process and the pharmaceutical compositions containing same |
| 08/16/2001 | WO2001059120A2 Il-17 like molecules and uses thereof |
| 08/16/2001 | WO2001059106A1 Novel g protein-coupled receptor proteins and dnas thereof |
| 08/16/2001 | WO2001059104A1 Partners of ptb1 domain of fe65, preparation and uses |
| 08/16/2001 | WO2001059103A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 08/16/2001 | WO2001059072A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 08/16/2001 | WO2001059071A2 Methods of preparing and using a viral vector library |
| 08/16/2001 | WO2001058956A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | WO2001058951A2 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/16/2001 | WO2001058945A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | WO2001058943A1 Novel collagen-like protein clac, precursor thereof and genes encoding the same |
| 08/16/2001 | WO2001058937A2 Interferon-alpha induced genes |
| 08/16/2001 | WO2001058936A2 Constructs for delivery of therapeutic agents to neuronal cells |
| 08/16/2001 | WO2001058916A2 Antibodies to ccr5 |
| 08/16/2001 | WO2001058915A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/16/2001 | WO2001058906A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058902A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058900A1 1h-imidazopyridine derivatives |
| 08/16/2001 | WO2001058899A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 08/16/2001 | WO2001058897A1 Benzthiazoles as tnf and pde-iv inhibitors |
| 08/16/2001 | WO2001058896A1 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 08/16/2001 | WO2001058895A1 Benzofuran carboxamides and their therapeutic use |
| 08/16/2001 | WO2001058893A2 Indol-3-yl derivatives and their use as integrin inhibitors |
| 08/16/2001 | WO2001058891A2 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
| 08/16/2001 | WO2001058890A1 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 |
| 08/16/2001 | WO2001058889A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| 08/16/2001 | WO2001058881A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 08/16/2001 | WO2001058879A1 2-phenylcarbamoyl-benzimidazoles |
| 08/16/2001 | WO2001058875A2 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 08/16/2001 | WO2001058489A1 Preventives/remedies for postoperative stress |
| 08/16/2001 | WO2001058479A1 Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| 08/16/2001 | WO2001058472A2 Botulinum toxin pharmaceutical compositions |
| 08/16/2001 | WO2001058470A2 Methods for enhancing the bioavailability of a drug |
| 08/16/2001 | WO2001058463A1 Neuronal cell division |
| 08/16/2001 | WO2001058462A2 Models, methods and materials relating to clinical conditions associated with reactive oxygen species |
| 08/16/2001 | WO2001058454A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| 08/16/2001 | WO2001058453A1 The use of mirtazapine for the treatment of sleep disorders |
| 08/16/2001 | WO2001058451A1 Tamper-resistant oral opioid agonist formulations |
| 08/16/2001 | WO2001058450A2 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 08/16/2001 | WO2001058447A1 Controlled-release compositions containing opioid agonist and antagonist |
| 08/16/2001 | WO2001058445A1 Therapy with cannabinoids in the treatment of cerebral tumor |
| 08/16/2001 | WO2001058443A1 TNF- α INHIBITORS |
| 08/16/2001 | WO2001058437A1 Nerve growth factor activity potentiating agents |
| 08/16/2001 | WO2001058435A1 Autonomic controlling agents |
| 08/16/2001 | WO2001058409A2 Method of reducing aluminum levels in the central nervous system |
| 08/16/2001 | WO2001058351A1 Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 08/16/2001 | WO2001051047A8 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 08/16/2001 | WO2001010893A3 Il-16 antagonists |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001010380A3 Benzanilides as potassium channel openers |
| 08/16/2001 | WO2001009115A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 08/16/2001 | WO2001009096A3 Potassium channel openers |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007435A3 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 08/16/2001 | WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |
| 08/16/2001 | WO2000061128A3 R-hydroxynefazodone |
| 08/16/2001 | WO2000059487A3 Flupirtine in the treatment of fibromyalgia and related conditions |
| 08/16/2001 | WO2000056356B1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 08/16/2001 | US20010014698 Method for preventing and treating alcoholism |
| 08/16/2001 | US20010014696 Therapeutic compositions (II) |
| 08/16/2001 | US20010014695 Therapy for degradation diseases; oxidation resistance |
| 08/16/2001 | US20010014691 Nervous system disorders |
| 08/16/2001 | US20010014689 Nervous system disorders |
| 08/16/2001 | US20010014683 Analgesics; side effect reduction |
| 08/16/2001 | US20010014680 1,4-piperazine derivatives |
| 08/16/2001 | US20010014678 Using mixture of a nicotine receptor antagonist and antidepressant and,or anxiolytic agent |
| 08/16/2001 | EP1123933A1 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent |
| 08/16/2001 | EP1123926A1 Piperazine derivatives for treatment of CNS disorders |
| 08/16/2001 | EP1123923A1 Dihydropyridine derivatives and drug compositions containing the same |
| 08/16/2001 | EP1123922A2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 08/16/2001 | EP1123706A1 Neuronal cell division |
| 08/16/2001 | EP1123704A1 Remedies for spinal canal stenosis |
| 08/16/2001 | EP1123509A2 Methods of diagnosing or prognosing alzheimer's disease |
| 08/16/2001 | EP1123414A1 Antisense modulation of integrin alpha 4 expression |
| 08/16/2001 | EP1123393A1 Follistatin-related protein zfsta2 |
| 08/16/2001 | EP1123392A1 Prv-1 gene and the use thereof |
| 08/16/2001 | EP1123388A1 Transgenic c. elegans as a model organism for research into alzheimer's disease |
| 08/16/2001 | EP1123296A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| 08/16/2001 | EP1123295A1 Bicyclic nitrogen heterocycles |
| 08/16/2001 | EP1123292A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123284A1 Method for the preparation of citalopram |
| 08/16/2001 | EP1123280A1 Serine protease inhibitor |
| 08/16/2001 | EP1123279A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123277A1 Epibatidine analogues as acetylcholine receptor antagonists |
| 08/16/2001 | EP1123272A1 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 08/16/2001 | EP1123269A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123268A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123267A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123109A1 Contulakin-g, analogs thereof and uses therefor |
| 08/16/2001 | EP1123100A1 Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof |
| 08/16/2001 | EP1123094A1 Therapeutic compositions (ii) |
| 08/16/2001 | EP1123091A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |